New directions for protease inhibitors directed drug discovery
Identifieur interne : 001127 ( Main/Exploration ); précédent : 001126; suivant : 001128New directions for protease inhibitors directed drug discovery
Auteurs : Yoshio Hamada [Japon] ; Yoshiaki Kiso [Japon]Source :
- Peptide Science [ 0006-3525 ] ; 2016-07.
Abstract
Proteases play crucial roles in various biological processes, and their activities are essential for all living organisms—from viruses to humans. Since their functions are closely associated with many pathogenic mechanisms, their inhibitors or activators are important molecular targets for developing treatments for various diseases. Here, we describe drugs/drug candidates that target proteases, such as malarial plasmepsins, β‐secretase, virus proteases, and dipeptidyl peptidase‐4. Previously, we reported inhibitors of aspartic proteases, such as renin, human immunodeficiency virus type 1 protease, human T‐lymphotropic virus type I protease, plasmepsins, and β‐secretase, as drug candidates for hypertension, adult T‐cell leukaemia, human T‐lymphotropic virus type I‐associated myelopathy, malaria, and Alzheimer's disease. Our inhibitors are also described in this review article as examples of drugs that target proteases. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 563–579, 2016.
Url:
DOI: 10.1002/bip.22780
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A12
- to stream Istex, to step Curation: 001A12
- to stream Istex, to step Checkpoint: 000033
- to stream Main, to step Merge: 001129
- to stream Main, to step Curation: 001127
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New directions for protease inhibitors directed drug discovery</title><author><name sortKey="Hamada, Yoshio" sort="Hamada, Yoshio" uniqKey="Hamada Y" first="Yoshio" last="Hamada">Yoshio Hamada</name></author><author><name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:46D5F7F977F18ED648965E857B09BE052495B727</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1002/bip.22780</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-DXFWS5MH-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001A12</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A12</idno><idno type="wicri:Area/Istex/Curation">001A12</idno><idno type="wicri:Area/Istex/Checkpoint">000033</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000033</idno><idno type="wicri:doubleKey">0006-3525:2016:Hamada Y:new:directions:for</idno><idno type="wicri:Area/Main/Merge">001129</idno><idno type="wicri:Area/Main/Curation">001127</idno><idno type="wicri:Area/Main/Exploration">001127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">New directions for protease inhibitors directed drug discovery</title><author><name sortKey="Hamada, Yoshio" sort="Hamada, Yoshio" uniqKey="Hamada Y" first="Yoshio" last="Hamada">Yoshio Hamada</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Medicinal Chemistry Laboratory, Kobe Pharmaceutical University, Motoyamakita, Kobe, 658‐8558, Higashinada‐ku</wicri:regionArea><wicri:noRegion>Higashinada‐ku</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Laboratory of Peptide Science, Nagahama Institute of Bio‐Science and Technology, Nagahama, 526‐0829, Tamura‐cho</wicri:regionArea><wicri:noRegion>Tamura‐cho</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Peptide Science</title><title level="j" type="sub">Emerging Peptide Science from Japan</title><title level="j" type="alt">PEPTIDE SCIENCE</title><idno type="ISSN">0006-3525</idno><idno type="eISSN">1097-0282</idno><imprint><biblScope unit="vol">106</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="563">563</biblScope><biblScope unit="page" to="579">579</biblScope><biblScope unit="page-count">17</biblScope><date type="published" when="2016-07">2016-07</date></imprint><idno type="ISSN">0006-3525</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-3525</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Proteases play crucial roles in various biological processes, and their activities are essential for all living organisms—from viruses to humans. Since their functions are closely associated with many pathogenic mechanisms, their inhibitors or activators are important molecular targets for developing treatments for various diseases. Here, we describe drugs/drug candidates that target proteases, such as malarial plasmepsins, β‐secretase, virus proteases, and dipeptidyl peptidase‐4. Previously, we reported inhibitors of aspartic proteases, such as renin, human immunodeficiency virus type 1 protease, human T‐lymphotropic virus type I protease, plasmepsins, and β‐secretase, as drug candidates for hypertension, adult T‐cell leukaemia, human T‐lymphotropic virus type I‐associated myelopathy, malaria, and Alzheimer's disease. Our inhibitors are also described in this review article as examples of drugs that target proteases. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 563–579, 2016.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Hamada, Yoshio" sort="Hamada, Yoshio" uniqKey="Hamada Y" first="Yoshio" last="Hamada">Yoshio Hamada</name></noRegion><name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:46D5F7F977F18ED648965E857B09BE052495B727
|texte= New directions for protease inhibitors directed drug discovery
}}
| This area was generated with Dilib version V0.6.33. |  |